A single lymphocyte culture system is described which produces both reliable fragile X expression and elongated chromosomes for prometaphase analysis. This system, which is based on that described by Wheater and Roberts in 1987, involves the deoxycytidine release of a thymidine block. Eight fragile X positive subjects had an average expression level of 26%, with a range of 12% to 45%, using the thymidine/deoxycytidine protocol. This was comiarable to the levels obtained in parallel cultares treated with thymidine alone or fluorodeoxyuridine.
allel cultares treated with thymidine alone or fluorodeoxyuridine.
Several techniques have been developed to produce elongated or prometaphase chromosomes for cytogenetic analysis, and in the last few years the use of an excess thymidine (300 mg/l) block to induce synchrony in lymphocyte cultures has become one of the standard techniques.'2 Thymidine is added the day before harvest to block the cell cycle at S phase and the block is released the following morning either by removal of the thymidine or addition of deoxycytidine.
Sutherland et al4 showed that similar levels of thymidine can be used to induce expression of some chromosome fragile sites, in particular fra(X)(q27), the fragile site associated with Martin-Bell syndrome. 5 The ability to use a single culture system to produce both reliable fragile X expression and elongated chromosomes would clearly be of advantage to a diagnostic cytogenetic laboratory.
Over a period of one year we have been using cultures treated with excess thymidine or fluorodeoxyuridine6 for the induction of fragile sites and a third culture treated with a thymidine block released Lymphocyte cultures were established by adding 0-2 ml of heparinised whole blood to 5 ml of RPMI 1640 culture medium supplemented with 10% fetal calf serum and containing penicillin (50 IU/ml), streptomycin (50 gg/ml), L-glutamine (1-4 mmol/l), and phytohaemagglutinin (0-05 ml Gibco M form). The cultures were incubated at 37°C for 72 or 96 hours before harvesting (as convenient for the laboratory). Thymidine (300 mg/1) was added 24 hours and colcemid (0-5 jg/ml) one hour before harvesting by using standard procedures. Control data were obtained from 36 patients screened for fragile X syndrome during the same period who were referred to the laboratory because of developmental delay. THY/DOC = thymidine block with deoxycytidine release as described in method (B). THY = unreleased thymidine treatment as described in method (A). FDU = fluorodeoxyuridine treatment as described in method (C).
Results
The expression levels of the fragile X chromosome observed in eight patients from five families are shown in the A good mitotic index of cells with elongated chromosomes for prometaphase analysis was obtained from all eight patients.
Discussion
Sutherland et al4 showed that an excess of thymidine (300 mg/l) can be used to induce fragile X expression, but that when thymidine synchronised cultures were released from the block by removing the thymidine, the level of expression of the fragile X chromosome was less than one third of the level observed in other fragile X induction regimens. Preliminary unpublished data of our own are consistent with this observation.
Sutherland et al4 also showed that the addition of deoxycytidine suppressed the thymidine induced expression of the fragile X chromosome if the concentration of deoxycytidine was high (300 mg/l); however, a lower concentration of deoxycytidine (100 mg/l) only suppressed the expression of the fragile X very slightly.
To produce elongated chromosomes the concentration of deoxycytidine used by Wheater and Roberts3 to release the thymidine block is much less than the concentrations used by Sutherland et 
